Application
Quality Control Testing
Evaluated by Western Blotting in mouse brain tissue lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected ADAMTS5 in mouse brain tissue lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected ADAMTS5 in lysate from rat brain tissue.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected ADAMTS5 in mouse articular cartilage tissue sections.
Affinity Binding Assay: A representative lot of this antibody bound with ADAMTS5 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Biochem/physiol Actions
Clone 1G12 is a ZooMAb® rabbit recombinant monoclonal antibody that detects ADAMTS5. It targets an epitope within 16 amino acids from the C-terminal half.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
A disintegrin and metalloproteinase with thrombospondin motifs 5 (UniProt: Q9UNA0; also known as ADAM-TS 5, ADAM-TS5, ADAMTS-5, A disintegrin and metalloproteinase with thrombospondin motifs 11 (ADAM-TS 11; ADAMTS-11), ADMP-2, Aggrecanase-2) is encoded by the ADAMTS5 (also known as ADAMTS11, ADMP2) gene (Gene ID: 11096) in human. A Disintegrin and Metalloprotease with Thrombospondin Motifs 5 (ADAMTS5) is a zinc-dependent metalloproteinase primarily involved in extracellular matrix remodeling. It consists of a catalytic domain, a disintegrin-like domain, thrombospondin type I repeats, a cysteine-rich domain, and a spacer domain, which collectively mediate its enzymatic and substrate-binding activities. It is predominantly localized in the extracellular matrix and secreted into various tissues, including cartilage and synovium. ADAMTS5 is a major aggrecanase, cleaving aggrecan, a key proteoglycan in cartilage, which is critical for maintaining joint integrity. Dysregulation of ADAMTS5 contributes to cartilage degradation, making it a central player in osteoarthritis (OA) pathogenesis. It plays a role in promoting extracellular matrix degradation in cancer metastasis, particularly in ovarian cancer, where it facilitates tumor cell invasion via interaction with Rab25-mediated NF- B signaling pathways. ADAMTS5 is upregulated in pathological conditions such as osteoarthritis and certain cancers. In osteoarthritis, its overactivation leads to progressive loss of aggrecan and cartilage matrix integrity, exacerbating joint inflammation and mechanical dysfunction. In ovarian cancer, elevated ADAMTS5 levels correlate with poor prognosis, as its proteolytic activities enable cancer cells to invade surrounding tissues. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Immunogen
KLH-conjugated linear peptide corresponding to 16 amino acids from the C-terminal half of human ADAMTS5.
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Preparation Note
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany